TABLE 2.

Comparison of PML cases and their matched controlsa

ParameterAll PML patients and their controlsPatients with laboratory-confirmed or definitive diagnosis and their controls
Odds ratio (95% CI)POdds ratio (95% CI)P
JCV-specific cellular immune response (estimates by 10-fold higher of parameter +1)
    All patients0.77 (0.36, 1.62)0.480.20 (0.03, 0.68)0.008
    Survivors1.19 (0.48, 3.05)0.710.50 (0.09, 2.08)0.34
    Nonsurvivors0.29 (0.05, 1.13)0.080.03 (0.00, 0.46)0.004
CMV-specific cellular immune response (estimates by 10-fold higher of parameter +1)
    All patients0.85 (0.46, 1.54)0.600.56 (0.19, 1.47)0.24
    Survivors0.87 (0.35, 2.07)0.751.41 (0.18, 11.50)0.73
    Nonsurvivors0.85 (0.38, 1.88)0.680.44 (0.11, 1.30)0.14
JCV VLP IgG response (estimates by 2-fold-higher parameter value)
    All patients1.31 (1.01,1.75)0.041.14 (0.83, 1.63)0.42
    Survivorsb1.73 (1.19, 2.70)0.0031.46 (0.91, 2.94)0.13
    Nonsurvivors0.86 (0.53, 1.34)0.500.88 (0.52, 1.43)0.62
JCV VLP IgM response (estimates by 2-fold-higher parameter value)
    All patients1.45 (0.91, 2.40)0.122.39 (0.99, 6.24)0.053
    Survivors1.44 (0.87,2.48)0.153.08 (1.02, 11.11)0.047
    Nonsurvivors1.48 (0.41, 5.32)0.531.51 (0.35, 6.65)0.56
  • a Odds of developing PML based on cellular and humoral immunity at time zero in all patients and in PML survivors and nonsurvivors (and their matched controls) separately. The results are based on logistic regression using Firth's bias reduction adjusted for matching. CI, confidence interval.

  • b If results are based on non-log-transformed JCV VLP IgG response instead, which is equally sensible based on the data, the results for survivors are significant both in all survivors (P = 0.001) and in survivors with laboratory-confirmed or definitive diagnosis and their controls (P = 0.03).